Special Issue "Cannabidiol: Advances in Therapeutic Applications and Future Perspectives"
Deadline for manuscript submissions: 31 March 2022.
Interests: experimental medicine; pharmacology; endocannabinoid system; mevalonate pathway; statins; glioblastoma
Interests: biochemistry; molecular biology; experimental medicine; pharmacology; endocannabinoid system; mevalonate pathway; innate immunity; angiogenesis; cancer
Cannabidiol (CBD) is one of the main natural cannabinoids found in Cannabis sativa. Due to the lack of psychotropic effects associated with Δ9THC and its good safety profile, CBD is the most interesting cannabinoid from a pharmacological point of view. Beneficial therapeutic effects have been reported in patients with inflammatory, neurodegenerative, and autoimmune diseases as well as in those with epilepsy and cancer. The use of CBD-based products in the form of high-concentration oil, powder and extract is permitted under current regulations. There is no evidence of its use for recreational purposes, nor have any health and safety problems been identified in relation to its consumption (WHO, 2018). In light of previous studies conducted, more and more countries have or are changing their rules on cannabis regulation to consider CBD as a medicinal product as well as a food supplement. Currently, the first CBD-based drug, GW Pharmaceuticals' Epidiolex®, has been approved in both the US and Europe for the treatment of some severe forms of epilepsy. Others such as Echo Pharmaceuticals' Arvisol® are in the advanced clinical development stage.
This Special Issue aims to provide readers with the most recent advances in this field. Authors are invited to submit relevant original articles, reviews or short communications for inclusion.
Dr. Maurizio Bifulco
Dr. Simona Pisanti
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- experimental medicine
- natural products
- inflammatory diseases
- autoimmune diseases
- neurodegenerative diseases